chufangao/CTO huggingface dataset:
Clinical trial NCT04542070: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
Official title: A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Acronym: SOLAR
Sponsor: ViiV Healthcare (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 687.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-11-09
Primary completion date: 2022-07-13
Completion date: 2023-04-17
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/
IPD time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Clinical trial NCT05528861: A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects With H-1 Antihistamine Refractory Chronic Spontaneous Urticaria
Acronym: MAVERICK
Sponsor: Allakos Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: No longer pursuing development
Enrollment: 127.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-26
Primary completion date: 2023-12-27
Completion date: 2024-04-18
Baseline population: Baseline analysis is reported on the safety population of the main study period. Baseline information of OLE subjects is not reported since it is already captured as part of the main study population.
Plan to share individual participant data: NO
Clinical trial NCT01462578: Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)
Official title: Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)
Acronym: RELAZA2
Sponsor: Technische Universität Dresden (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 93.0 (ACTUAL)
Number of arms: 1.0
Start date: 2011-09-30
Primary completion date: 2018-08-31
Completion date: 2021-02-28
Clinical trial NCT02665364: Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
Official title: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus
Sponsor: Neovacs (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Reorganization proceedings of the sponsor
Enrollment: 185.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-23
Primary completion date: 2018-03-15
Completion date: 2020-02-04
Baseline population: A total of 185 subjects were randomized. One subject was randomized in IFN-K group and did not receive IFN-K. 184 subjects were treated; 91 subjects received IFN-K and 93 subjects received placebo.
Clinical trial NCT03529084: Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Official title: A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Decision by Sponsor not to continue with the trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-24
Primary completion date: 2020-08-13
Completion date: 2024-06-03
Plan to share individual participant data: UNDECIDED
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Clinical trial NCT02847637: A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
Official title: A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients Without Inhibitors
Acronym: HAVEN 3
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 152.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-09-27
Primary completion date: 2017-09-15
Completion date: 2022-05-12
Clinical trial NCT04727606: Research Project: Pilot Study on Oral Urea Use in Patients at High Risk of Kidney Stone Recurrence
Official title: Research Project: Pilot Study on Oral Urea Use in Patients at High Risk of Kidney Stone Recurrence
Acronym: Ure-Na
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: We never got Health Canada approval
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-01-15
Primary completion date: 2024-01-15
Completion date: 2024-06-15
Plan to share individual participant data: NO
Clinical trial NCT04382586: Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
Official title: A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 63.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-06
Primary completion date: 2021-02-01
Completion date: 2021-02-01
Baseline population: The Intent-to-Treat (ITT) Analysis Set includes all randomized participants
Plan to share individual participant data: YES
Clinical trial NCT03367689: A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent
Official title: A Two-stage Simon Design Phase II Study for NOn-BRCA Metastatic BReast Cancer (MBC) Patients With Homologous Recombination Deficiency Treated With OLAparib Single Agent
Acronym: NOBROLA
Sponsor: MedSIR (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Very slow recruitment due to subject profile
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-17
Primary completion date: 2021-07-31
Completion date: 2021-12-31
Clinical trial NCT03088878: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
Official title: A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Sponsor: Oncternal Therapeutics, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 102.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-01-03
Primary completion date: 2024-09-25
Completion date: 2024-09-25
Plan to share individual participant data: NO
Clinical trial NCT05435742: SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)
Official title: A Randomized, Double-blind, Placebo-controlled Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Repeated Subcutaneous Administration of SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN) After the End of Chemotherapeutic Treatment
Sponsor: Sonnet BioTherapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Lack of Enrollment
Enrollment: 9.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-10-27
Primary completion date: 2024-03-17
Completion date: 2024-03-17
Plan to share individual participant data: NO
Clinical trial NCT03399578: Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)
Official title: A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers
Sponsor: University of Oxford (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The scientific questions proposed remain relevant, but will now be addressed in a larger phase II immunogenicity trial of the ChAdOx1 MERS vaccine given at 2 doses.
Enrollment: 29.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-03-14
Primary completion date: 2021-09-17
Completion date: 2021-09-17
Clinical trial NCT04362332: Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19
Official title: An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19
Acronym: ARCHAIC
Sponsor: UMC Utrecht (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be expected we need more than 1000 inclusions
Enrollment: 25.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-04-14
Primary completion date: 2020-06-08
Completion date: 2020-06-08
Plan to share individual participant data: YES
IPD time frame: 12 months
Clinical trial NCT02354911: Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy
Official title: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study of the Safety and Efficacy of Autologous Immunoregulatory Dendritic Cells in Patients With Type 1 Diabetes
Sponsor: DiaVacs, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding for study not procured.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-10-31
Primary completion date: 2024-02-16
Completion date: 2024-02-16
Clinical trial NCT03840200: A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Official title: A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 51.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-06-12
Primary completion date: 2021-12-07
Completion date: 2022-01-04
Baseline population: Safety population included all participants who were treated with at least one dose of the study treatment.
Clinical trial NCT04382911: Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
Official title: Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-07
Primary completion date: 2022-07-11
Completion date: 2022-07-11
Plan to share individual participant data: YES
IPD sharing description: Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
IPD time frame: 9 to 36 months following publication
IPD access criteria: The investigator who proposes to use the data has approval from an IRB, IEC, or REB, as applicable, and an executed data use/sharing agreement with UNC.
Clinical trial NCT04543955: Telotristat With Lutathera in Neuroendocrine Tumors
Official title: Study of Telotristat (Xermelo) in Combination With Luetetium Lu177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors
Sponsor: University of Kentucky (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor cancelled research
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-13
Primary completion date: 2022-06-03
Completion date: 2022-06-03
Baseline population: Research cancelled and 0 participants enrolled in Arm 2
Plan to share individual participant data: NO
Clinical trial NCT04569786: Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated based on an interim assessment of immunogenicity.
Enrollment: 232.0 (ACTUAL)
Number of arms: 9.0
Start date: 2020-10-29
Primary completion date: 2021-02-18
Completion date: 2021-02-18
Limitations and caveats: The study was terminated based on an interim assessment of immunogenicity.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04853043: Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
Official title: APK Mutant: A Single Arm Phase II Study of Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
Acronym: APK Mutant
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: PI Determination - Slow recruitment, funding concerns, poor response to treatment
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-11-03
Primary completion date: 2024-02-20
Completion date: 2024-05-03
Plan to share individual participant data: NO
Clinical trial NCT03434041: A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Official title: A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 252.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-25
Primary completion date: 2021-04-13
Completion date: 2021-04-13
Limitations and caveats: As esketamine has known transient dissociative effects that are difficult to blind, these specific treatment-emergent events could have biased the staff who provided and observed the dosing. Therefore, to ensure an unbiased efficacy evaluation, independent, remote (by telephone), blinded MADRS raters were used to assess the treatment response.
Clinical trial NCT00867048: Strategic Timing of Antiretroviral Treatment
Official title: Strategic Timing of AntiRetroviral Treatment
Acronym: START
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 4688.0 (ACTUAL)
Number of arms: 2.0
Start date: 2009-04-15
Primary completion date: 2022-07-27
Completion date: 2022-07-27
Clinical trial NCT04979949: Booster Vaccination Against COVID-19
Official title: Double-Blind, Randomized, Controlled, Multi-Centered, Phase 2 Clinical Trial to Determine the Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2
Sponsor: Health Institutes of Turkey (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 222.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-12
Primary completion date: 2022-03-09
Completion date: 2022-06-06
Clinical trial NCT03618264: Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Postoperative Pain After Craniotomy
Official title: Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine vs. Ropivacaine for Relief of Postoperative Pain After Craniotomy in Adults
Sponsor: Beijing Tiantan Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 140.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-04
Primary completion date: 2019-08-15
Completion date: 2020-02-13
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01856439: Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
Official title: A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.
Sponsor: Sio Gene Therapies (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: As a result of termination of development of Prosavin, it is no longer possible for Sio to either commence or to continue any related clinical trials.
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2011-05-31
Primary completion date: 2021-11-30
Completion date: 2022-04-30
Plan to share individual participant data: NO
Clinical trial NCT02096588: Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Official title: Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The Principal Investigator left Johns Hopkins
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-05-20
Primary completion date: 2017-04-25
Completion date: 2023-07-26
Plan to share individual participant data: NO
Clinical trial NCT03701711: Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study
Official title: A Phase I Study of Lenalidomide in Combination with Dexamethasone in Anti-MAG Demyelinating Sensorimotor Neuropathy
Sponsor: Ohio State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Higher than expected occurrence of VTE (venous thromboembolic event)
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-10
Primary completion date: 2022-02-28
Completion date: 2022-02-28
Clinical trial NCT04655183: Study of M4344 in Combination With Niraparib
Official title: A Phase I Dose Escalation Study of ATR Inhibitor M4344 in Combination With Niraparib in Participants With Advanced Solid Tumors Followed by Phase II Cohort Expansion in Participants With Breast Cancer With DNA Damage Response (DDR) Mutations
Sponsor: EMD Serono (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Trial withdrawn based on portfolio prioritization; oral ATRi M1774 in combination with niraparib is under investigation in DDRiver Solid Tumor 301
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-12-01
Primary completion date: 2023-09-01
Completion date: 2023-09-01
Plan to share individual participant data: YES
IPD sharing description: Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html
Clinical trial NCT05010525: A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
Official title: A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
Acronym: REACH
Sponsor: Antengene Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study
Enrollment: 8.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-09-01
Primary completion date: 2022-11-14
Completion date: 2022-11-14
Clinical trial NCT04632706: Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
Official title: A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers
Sponsor: MedinCell S.A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-09-22
Primary completion date: 2021-03-09
Completion date: 2021-03-09
Plan to share individual participant data: NO
Clinical trial NCT04054687: Intranasal TXA for Anterior Epistaxis in the Emergency Department
Official title: Intranasal TXA for Anterior Epistaxis in the Emergency Department
Sponsor: Mercy Health Ohio (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: Due to coronavirus pandemic
Enrollment: 86.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2019-11-07
Primary completion date: 2021-04-30
Completion date: 2021-05-31
Clinical trial NCT04764630: Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone
Official title: Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone
Sponsor: Food and Drug Administration (FDA) (FED)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 21.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-01
Primary completion date: 2021-03-20
Completion date: 2021-03-20
Plan to share individual participant data: YES
IPD sharing description: Individual patient data will be shared at the time of the primary publication.
IPD time frame: Individual patient data will be shared at the time of the primary publication, which is anticipated to be within 1 year of study completion.
IPD access criteria: No restrictions.
Clinical trial NCT05021484: Felzartamab in Late Antibody-Mediated Rejection
Official title: Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection - A Phase 2 Pilot Trial
Sponsor: Medical University of Vienna (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-06
Primary completion date: 2024-03-07
Completion date: 2024-03-07
Plan to share individual participant data: NO